Systemic Lupus Erythematosus

The decision is supported by data from the phase 2b JASMINE study which will be presented at a future medical meeting.

Subcutaneous anifrolumab for SLE met its primary BICLA endpoint at 52 weeks and significantly increased DORIS-defined remission and low disease activity.

Cuda discussed the link between SLE disease activity and cognitive deficits,

New research at ACR 2025 highlights the link between cognitive impairment and disease activity in SLE.

Phase 2 trial shows ianalumab achieves sustained lupus disease control, supports steroid tapering, and increases time in remission over 1 year.

Phase 3 data show dapirolizumab pegol improved remission and disease stability in lupus; a second trial and patient-reported outcomes are now underway.

At ACR 2025, Vital discussed phase 3 data showing dapirolizumab pegol improved remission and stabilized disease activity in patients with lupus.

Jin discussed new evidence supporting the immune-modulating effects of low-dose IL-2 at ACR 2025.

However, a notable higher rate of treatment-related adverse events warrants caution.

Upadacitinib reduced glucocorticoid doses and improved disease activity over 104 weeks.

Nearly a third of patients with lupus in APPEAL reported falls, with disease activity, depressive symptoms, and medication use among key risk factors.

Santerus AG is preparing to initiate clinical trials of its blood purification technology in a variety of indications.

New phase 3 trial data reveals Dapirolizumab pegol significantly reduces disease activity and fatigue in systemic lupus erythematosus patients, promising improved treatment outcomes.

A recent study reveals significant variations in biologic use among pregnant patients with autoimmune diseases, highlighting the need for tailored risk-benefit assessments.

A recent meta-analysis confirms belimumab's superior efficacy over placebo in treating systemic lupus erythematosus, potentially informing clinical management strategies.

Patients in the anifrolumab arm also had lower rates of damage accrual.

Clowse discussed findings from the phase 3 PHOENYCS GO trial presented at the 2024 ACR Convergence.

The phase 3 PHOENYCS GO trial met its primary endpoint in achieving BICLA response at week 48 compared with placebo.

A-319 has been well-tolerated so far and dose-escalation is ongoing in the phase 1 trial.

A new cohort study including over 6 million participants has found an increased likelihood of Behçet disease, alocpecia, bulbous pemphigoid and other disorders post-COVID infection.

Four of 5 participants with follow-up reaching 3 months have achieved SRI-4 disease responses.

A study found that high ultraprocessed food consumption increases the risk of SLE by 56%, with an even higher risk for anti-dsDNA positive SLE at 105%.

The therapy demonstrated superior efficacy in combination with SOC over SOC alone.